Veradermics

Veradermics is growing its Medical Affairs and Finance teams. We’re currently #hiring an Accounting Manager and 2–3 Medical Science Liaisons. Click here to learn more and apply: https://lnkd.in/e4ar8zFX  #Veradermics #DermatologyInnovation #Biotechjobs #hiring #medicalaffairs #financejobs  

Veradermics is #hiring two critical executive support roles: Executive Assistant to the CEO, and Executive Assistant (CFO/CCO) & Office Manager. Click here to learn more and apply: https://lnkd.in/e4ar8zFX  #Veradermics #DermatologyInnovation #Biotechjobs #hiring #executiveassistant #eajobs

Veradermics is #hiring a Contract Specialist and a Vice President of Corporate Brand and Communications. Click here to learn more and apply: https://lnkd.in/e4ar8zFX  #Veradermics #DermatologyInnovation #BiotechCareers #hiring

2025 has been a year filled with milestones for Veradermics.  The company secured an oversubscribed Series C financing and initiated our Phase 3 registration-directed clinical trials for men and women with pattern hair loss including the first such trial we are aware of for a potential oral treatment in female pattern hair loss. We’re proud to be sharing our progress in dermatology and aesthetics.    Thank you to our exceptional team whose confidence fuels our mission to deliver solutions that people and providers can trust.  We look forward to building on this momentum and continuing to drive innovation forward in 2026! #dermatology #aesthetics #innovation #NewYear 

We are proud to share our CEO, Reid Waldman, has been featured as an All-Star Alumni on the 2025 U.S. Forbes #30under30 healthcare list! Under Reid’s leadership, Veradermics is advancing our lead investigational asset, VDPHL01—bringing us closer to developing potentially new therapeutics for commonly overlooked conditions, including pattern hair loss. Congrats, Reid!

https://lnkd.in/ecMyp_Wu

Today, we are excited to announce that we have completed enrollment in our Phase 2/3 registration-directed clinical trial for male pattern hair loss, evaluating VDPHL01, the potential first-ever extended-release oral minoxidil.      Pattern hair loss affects an estimated 50 million men in the U.S., yet there is only one FDA-approved oral option and no non-hormonal oral treatments available for men. Completing enrollment brings us one step closer to potentially delivering meaningful innovation in hair loss, where new options are long overdue.    Learn more: bit.ly/4qnLLF1     #dermatology #aesthetics #patternhairloss #clinicaltrials #innovation

Congratulations to our CEO, Reid Waldman, who was named Entrepreneur of the Year by BioCT and Shipman & Goodwin LLP!    This award celebrates leaders who are catalyzing and transforming the life sciences ecosystem in the Connecticut community and beyond. Reid has been recognized for his leadership at Veradermics, and his fierce commitment to advancing innovative solutions to fill critical treatment gaps in dermatology, including pattern hair loss.     Our team is so proud to see his vision and impact recognized by the broader community. Congrats again, Reid! #leadership #innovation #enterpreneur 

Today, we are proud to share that our lead investigational product, VDPHL01, is currently in a Phase 2/3 registration-directed clinical trial for female pattern hair loss, marking the first Phase 3 trial in women for an oral treatment.    An estimated 30 million women are affected by pattern hair loss in the U.S. and despite its prevalence, there is still no FDA-approved oral treatment for pattern hair loss in women.    We are committed to filling this gap, and excited about VDPHL01’s potential to transform the treatment landscape for women.     Learn more: bit.ly/3JJDWK6    #femalepatternhairloss #androgeneticalopecia #hairloss #innovation #clinicaltrials